Efficacy of everolimus with reduced-exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial-Reference-Cited by-同舟云学术

Efficacy of everolimus with reduced-exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial

Published:2015-02-24 Issue:5 Volume:28 Page:633-639
ISSN:1121-8428
Container-title:Journal of Nephrology
language:en
Short-container-title:J Nephrol

Author:

Carmellini Mario,Garcia Valter,Wang Zailong,Vergara Marcela,Russ Graeme

Publisher

Springer Science and Business Media LLC

Subject

Nephrology

Link

http://link.springer.com/content/pdf/10.1007/s40620-015-0180-6.pdf

Reference30 articles.

1. Flechner SM, Kobashigawa J, Klintmalm G (2008) Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 22:1–15

2. Sharif A, Shabir S, Chand S, Cockwell P, Ball S, Borrows R (2011) Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol 22:2107–2118

3. Ruiz R, Klintmalm GB (2012) Renal-sparing regimens employing new agents. Curr Opin Organ Transplant 17:619–625

4. Su L, Tam N, Deng R, Chen P, Li H, Wu L (2014) Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis. Int Urol Nephrol 46:2035–2044

5. Gurk-Turner C, Manitpisitkul W, Cooper M (2012) A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor. Transplantation 94:659–668

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Problem to solution; from mammalian skin grafts to renal allograft rejection: a tale of 66 years of evolution of our understanding;Journal of the Pakistan Medical Association;2023-05-15

2. Seeking Standardized Definitions for HLA-incompatible Kidney Transplants: A Systematic Review;Transplantation;2022-08-02

3. Managing immunosuppressive therapy in potentially cured post‐kidney transplant cancer (excluding non‐melanoma skin cancer): an overview of the available evidence and guidance for shared decision‐making;Transplant International;2021-09-27

4. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients;Cochrane Database of Systematic Reviews;2019-12-16

5. Mammalian Target of Rapamycin Inhibitors Combined With Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis;Transplantation;2019-10